Hepatitis C virus treatment

The current preferred treatment regimen for HCV infection is a combination of peginterferon alfa (given by injection) plus ribavirin (given orally).

Interferons are human proteins that directly inhibit viral replication and stimulate the body's immune response. Several different types of interferon have been studied to treat HCV. Conventional interferon alfa, the previous standard HCV therapy, was injected three times per week. Pegylated interferon, or peginterferon alfa, combines the interferon molecule with a coating of polyethylene glycol. Pegylation allows for more targeted cellular delivery and slower removal of the drug from circulation, in turn allowing for once-weekly dosing.

Two forms of peginterferon alfa have been licensed in Europe. Viraferon Peg or Peg-Intron is peginterferon alfa 2b, manufactured by Schering-Plough, licensed in 2001. Pegasys is peginterferon alfa 2a, made by Roche. Both forms of peginterferon are injected subcutaneously (under the skin) once weekly. It is not yet known whether the two types of pegylated interferon differ in efficacy or tolerability, although a head-to-head comparison trial is underway.

The oral drug ribavirin is not effective against HCV when taken alone, but improves response rates and appears to help prevent relapse when used with interferon. European approval of ribavirin, in combination with interferon, was granted in May 1999. In Europe, ribavirin is marketed under the brand names Copegus, Rebetol and Virazole.

Peginterferon plus ribavirin works better than non-pegylated interferon plus ribavirin,1,2 which in turn is more effective than interferon monotherapy.3,4,5

Treatment response rates and predictors of response

In HIV-negative people, the sustained virological resppnse (SVR) rate using peginterferon plus ribavirin is around 45% for people with genotype 1 and 80% for those with genotypes 2 or 3. A recent study found slightly higher sutained virological response rates in children: 48% for genotype 1 and 100% for genotypes 2 and 3.6 Factors that predict poorer response include male gender, older age, HCV genotype 1, higher HCV viral load, and advanced liver disease. In addition, studies show that people of African descent are less likely to respond to interferon-based therapy.7 8 9

The usual recommended course of treatment is 48 weeks for people with HCV genotype 1 and 24 weeks for people with genotypes 2 or 3. Some studies suggest that longer treatment duration may improve response rates, especially for HIV/HCV co-infected people.

Numerous studies have shown that response to therapy at 12 weeks predicts whether or not a person will achieve a sustained virological response six months after treatment is completed. If an HCV viral load reduction of at least 2 log10 has not been achieved by this time, many experts recommend discontinuing HCV therapy given the high incidence of side-effects and the low likelihood of achieving a sustained response.

Varying lengths of treatment courses have been studied. For HCV genotypes 2 or 3, 24 weeks of therapy has been demonstrated as generally sufficient to achieve SVR. One randomised trial has shown that patients with genotypes 2 or 3 may be able to stop HCV therapy after only 12 weeks, with similar SVR rates to that achieved after 24 weeks.10

Some doctors use peginterferon monotherapy as an initial treatment in people with less severe hepatitis C and those most likely to achieve a good response, and add ribavirin only if interferon alone has failed to produce undetectable HCV viral load after 12 weeks of treatment, or in case of subsequent relapse. In some individuals, peginterferon alone is an effective treatment, and this approach reduces the risk of a serious ribavirin side-effect called haemolytic anaemia.11 12 13 Peginterferon monotherapy has also shown benefit in treating acute HCV infection in HIV-positive individuals.

Despite the evidence that peginterferon is much more effective than conventional interferon, the combination of peginterferon and ribavirin has not received uniform funding throughout the United Kingdom.

Treatment response rates in co-infected individuals

Research shows that HIV/HCV co-infected people do not respond as well to hepatitis C treatment as those with HCV alone. However, a number of recent studies in Europe and the United States conducted in individuals with well-controlled HIV disease have produced promising results, including people with hard-to-treat genotype 1.

The largest co-infection study to date, known as APRICOT, included 868 co-infected individuals. In this study, those treated with peginterferon alfa 2a plus ribavirin for 48 weeks had an SVR rate of 40% (29% for genotype 1; 62% for genotypes 2 or 3).14

In the American ACTG 5071 study, which included 133 co-infected people, the SVR rate using the same regimen was 27% (14% for genotype 1; 73% for genotypes 2 or 3).15 This study produced a good end-of-treatment response rate, but many individuals later relapsed.

The French RIBAVIC study, which included 412 co-infected participants, produced a less impressive SVR rate of 27% (15% for genotypes 1 or 4; 44% for genotypes 2 or 3) using peginterferon alfa 2b plus ribavirin.16

A Spanish study of 95 co-infected individuals found an SVR rate of 44% for interferon alfa 2b plus ribavirin (38% for genotype 1; 53% for genotypes 2 or 3). This was the highest response rate yet seen in co-infected individuals with genotype 1.17

In early 2008, results from the SLAM-C study (US AIDS Clinical Trials Group study 5178) indicated that extended maintenance therapy with pegylated interferon does not reduce the rate of liver fibrosis progression in HIV/hepatitis C virus co-infected individuals who do not respond to combination treatment for hepatitis C.18

In the SLAM-C study (US AIDS Clinical Trials Group study 5178), 330 HIV/hepatitis C coinfected patients were enrolled, all but one of whom were initially treated with standard anti-hepatitis therapy consisting of 180 mcg once-weekly pegylated interferon alfa-2a (Pegasys) plus 1000-1200 mg/day weight-based ribavirin. Most participants had well-controlled HIV disease, with a median CD4 cell count of 498 cells/mm3 and three-quarters having undetectable HIV viral load (below 50 copies/ml).

Response to hepatitis C therapy was assessed at 12 weeks. At this point, 56% of patients achieved early virological response (at least a 2 log10 drop in HCV viral load), including 42% with undetectable hepatitis C RNA. This was a higher rate than the 41% seen in ACTG 5071, which used a lower dose of ribavirin (800mg/day regardless of weight). Factors significantly associated with early response were HCV genotypes 1 or 4 and white race/ethnicity. Other related factors were male sex, less fibrosis and better liver function (lower ALT level) at baseline, and higher neutrophil and haemoglobin levels. The remainder of the study participants were classified as non-responders. Although the standard duration of hepatitis treatment is 24 weeks for HCV genotypes 2 and 3 or 48 weeks for genotypes 1 and 4, people who do not experience early virological response by week 12 are unlikely to go on to achieve sustained response.

The 86 non-responders were then randomised either to receive maintenance therapy with the same dose of pegylated interferon monotherapy for 72 weeks or to be observed without further treatment. In April 2007, the trial’s safety monitoring committee stopped the maintenance therapy stage of the study early after it failed to show any difference in fibrosis progression between treated and untreated patients. In part, this was attributable to an unexpectedly low rate of progression in the observation group. Though enrolment in the trial was halted, observation is ongoing.

These findings in HIV/hepatitis C co-infected patients were somewhat similar to recently reported results from the HALT-C trial, which found that long-term, low-dose pegylated interferon did not reduce the rate of fibrosis progression amongst non-responders with hepatitis C monoinfection.

It is not yet clear why the SVR rates varied so much among these trials, but there were some important differences in study populations. For example, ACTG 5071 included more people of African descent (about one-third) than APRICOT (about one-tenth), a group that responds less well to treatment. RIBAVIC included patients with more advanced liver disease and more current and past IDUs. Also, the discontinuation rate in this study was high: more than 40%. Taken as a whole, these studies cannot show whether peginterferon alfa 2a (Pegasys) or peginterferon alfa 2b (Viraferon Peg / Peg-Intron) works better.

As is the case for people with HCV alone, higher baseline HCV viral loads tend to predict poorer likelihoods of SVR for co-infected people – at least for those with HCV genotype 1. A trend has been observed toward better response in people with higher baseline CD4 cell percentages.

Also, as for people with HCV alone, response to treatment at 12 weeks predicts whether or not co-infected individuals will ultimately achieve a sustained virological response.19 20 21 22 Newer studies have suggested that early virological response at eight or even four weeks might be adequately predictive of SVR, at least for certain genotypes,23 but there is not yet a consensus on this in clinical practice.

A major concern for HIV/HCV co-infected people has been the relatively high rate of relapse after clearing HCV.24 25 26 In the APRICOT, ACTG A5071 and RIBAVIC studies, in which participants received 48 weeks of treatment, 10 to 15% of people with an end-of-treatment response relapsed during the subsequent six months. The ACTG 5071 researchers suggested that their high relapse rate may have come about because the study started patients on lower initial doses of ribavirin in order to minimise toxicity. People with higher HCV viral loads are also more likely to experience relapse after initially successful therapy.

Treatment success is clearly dose-dependent. Studies in which doses of either ribavirin or peginterferon were reduced due to treatment toxicity have shown poorer response. Conversely, increases in ribavirin dose have shown better results, albeit with greater toxicity. In the Spanish PRESCO trial, early and sustained responses to daily ribavirin doses of 1000mg in patients who weighed less than 75 kg, and 1200mg in those who weighed more, were superior to those in the APRICOT trial, which used a dose of 800mg. However, extended treatment periods were also used in the adjusted-dose trial, which were associated with better response.27  Increased doses of ribavirin lead to increased likelihood of anaemia, requiring treatment with erythropoietin.

Given their lower response rates, it is reassuring that hepatitis C treatment appears to slow liver disease progression in co-infected individuals, as it does in people with HCV alone.28

People co-infected with HCV genotypes 2 and 3, who had high HCV viral loads at baseline and good responses after four weeks of treatment, had a higher likelihood of sustained SVR if treatment was continued for an additional 20 weeks after the 24-week period. Longer courses did not show additional benefit in treating HCV genotypes 1 or 4.

In co-infected individuals who did not achieve SVR after the first course of treatment, repeating the course of HCV treatment has shown mixed results.

Other factors that may influence response to hepatitis C treatment in co-infected individuals are being identified. Insulin resistance may be an important determinant of poor response; in one study the absence of insulin resistance tripled the likelihood of SVR (OR = 3.3).29 Abacavir use has been associated with poorer rates of SVR; an intracellular interaction between abacavir and ribavirin may be responsible. Nevirapine has been associated with better rates of SVR as compared to lopinavir/ritonavir (Kaletra); whether this is because nevirapine has any direct activity against HCV is not known.30


  1. Fried MW et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982, 2002
  2. Manns MP et al. Peginterferon-alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965, 2001
  3. McHutchison JG et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New Engl J Med 339: 1485-1492, 1998
  4. Poynard T et al. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group, 1998
  5. Reichard O et al. Randomised, double-blind, placebo-controlled trial of interferon with and without ribavirin for chronic hepatitis C. Lancet 351: 83-87, 1998
  6. Wirth S et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatol 41(5): 1013-1018, 2005
  7. Jeffers LJ et al. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 39: 1702-1708, 2004
  8. McHutchison JG et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group, 2000
  9. Muir A et al. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. New Engl J Med 350: 2265-2271, 2004
  10. Mangia A et al. Peginterfereon alfa-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3. N Engl J Med 352: 2609-2617, 2005
  11. Heathcote EJ et al. Peginterferon alpha-2b in patients with chronic hepatitis C and cirrhosis. New Engl J Med 343: 1673-1680, 2000
  12. Zeuzem S et al. Peginterferon alfa-2a in patients with chronic hepatitis C. New Engl J Med 343: 1666-1672, 2000
  13. Reddy KR et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 33: 433-438, 2001
  14. Torriani FJ et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. New Engl J Med 351: 438-450, 2004
  15. Chung R et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis in HIV-coinfected persons. N Engl J Med 351: 451-459, 2004
  16. Carrat F et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 292: 2839-2848, 2004
  17. Laguno M et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV coinfected patients. AIDS 18: F27-F36, 2004
  18. Sherman K et al. Sustained long-term antiviral maintenance with pegylated interferon in HCV/HIV co-infected patients: early viral response and effect on fibrosis in treated and control patients. Fifteenth Conference on Retroviruses and Opportunistic Infections, Boston, abstract 59, 2008
  19. Camino N et al. Early HCV-RNA clearance in HIV/HCV coinfected patients who begin treatment with pegylated interferon plus ribavirin. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, abstract H-1753, 2004
  20. Crespo M et al. 55th Annual Meeting of the American Society for the Study of Liver Diseases, Boston, abstract 428, 2004
  21. Rodriguez-Torres M et al. Predictability of sustained virological response at week 4 in HIV-HCV co-infected patients treated with peginterferon alfa-2a (40KD) (Pegasys) + ribavirin (Copegus) in the AIDS Pegasys Ribavirin International Co-infection Trial (APRICOT). ICAAC adstract H01751, 2004a
  22. Soriano V et al. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin. Antivir Ther 9: 505-509, 2004
  23. Cargnel A et al. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART. Antivir Ther 10: 309-317, 2005
  24. Hoffman-Terry M et al. Safety and efficacy of 40 Kda peginterferon alfa-2b (Pegasys) in the treatment of pts co-infected with HIV and HCV: Preliminary results from a randomized, multicenter trial. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, abstract H-1725, 2002
  25. Soriano V et al. Relapses of chronic hepatitis C in HIV-infected patients who responded to interferon therapy. AIDS 11: 400-401, 1997
  26. Perez-Olmeda M et al. Hepatitis C virus (HVC) relapses following the end of anti-HCV therapy are more frequent in HIV-co-infected patients. Second International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, abstract, 2003
  27. Nunez M et al. Efficacy and safety of pegInterferon-alpha 2a plus ribavirin for the treatment of hepatitis C in HIV coinfected patients: the PRESCO trial. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, abstract V-1148, 2004
  28. Lissen E et al. Histological response to peginterferon alfa-2a (40KD) (Pegasys) plus ribavirin (Copegus) in patients with HIV-HCV co-infection: results of the AIDS Pegasys Ribavirin International Co-Infection Trial (APRICOT). 55th Annual Meeting of the American Society for the Study of Liver Diseases, Boston, abstract 174, 2004
  29. Ryan P et al. Insulin resistance impairs response to interferon plus ribavirin in patients coinfected with HIV and hepatitis C virus. J Acquir Immune Defic Syndr, advance online publication, 2010
  30. Mira J et al. Concomitant nevirapine therapy is associated with higher efficacy of pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients. Eighteenth International AIDS Conference, Vienna, abstract TUAB0101, 2010

Hepatitis information

For more information on hepatitis visit infohep.org.

Infohep is a project we're working on in partnership with the European Liver Patients Association (ELPA).

Visit infohep.org >
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap